← Leaderboards
Sunil David
Virovax Llc
$7,760,439
Attributed
$7,760,439
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.3M · FY2019–22$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
Funding mix
By agency
NIH$7,760,439 · 1
By mechanism
N01$7,760,439 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adjuvant”
- Ted Ross · University Of Georgia$68,763,143
- Jay Evans · University Of Montana$43,101,450
- Valerie Fremont · Quality Biological, Inc.$19,261,930
- Aaron Esser-Kahn · University Of Chicago$13,698,058
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$10,000,000
- Garcia-Sastre Adolfo · Icahn School Of Medicine At Mount Sinai$8,560,974
Research focus
AdjuvantFlavivirusTlr7 GeneVaccinesAgonistWest Nile VirusDengueZika Virus VaccineHuman DiseaseImmunologicsSupport ContractsInvestigationPathogenLicensureZika VirusZika2019-NcovMeningitisMiddle East Respiratory SyndromeNeurologicNorth AmericaOryctolagus CuniculusPowassan VirusProgram Development
Grant awards (5)
Adjuvant Development in the context of vaccines for Zika, Dengue and West Nile virus$1,983,970
N01 · FY2022 · AI · contact PI
Develop a candidate subunit vaccine for Powassan Virus and West Nile virus adjuvanted with Alhydroxiquim-II$274,999
N01 · FY2022 · AI · contact PI
Adjuvant Development in the context of vaccines for Zika, Dengue and West Nile virus$3,635,428
N01 · FY2020 · AI · contact PI
ADJUVANT DEVELOPMENT PROGRAM - COVID-19 Supplement$649,995
N01 · FY2020 · AI · contact PI
Adjuvant Development in the context of vaccines for Zika, Dengue and West Nile virus$1,216,047
N01 · FY2019 · AI · contact PI